NUV | RMI | NUV / RMI | |
Gain YTD | 2.068 | -3.473 | -60% |
Net Assets | 1.83B | 96.8M | 1,892% |
Total Expense Ratio | 0.47 | 3.01 | 16% |
Turnover | 21.00 | 66.00 | 32% |
Yield | 4.22 | 1.38 | 306% |
Fund Existence | 38 years | 7 years | - |
NUV | RMI | |
---|---|---|
RSI ODDS (%) | 2 days ago70% | N/A |
Stochastic ODDS (%) | 2 days ago82% | 2 days ago82% |
Momentum ODDS (%) | 2 days ago69% | 2 days ago81% |
MACD ODDS (%) | 2 days ago76% | 2 days ago69% |
TrendWeek ODDS (%) | 2 days ago70% | 2 days ago74% |
TrendMonth ODDS (%) | 2 days ago74% | 2 days ago73% |
Advances ODDS (%) | 2 days ago76% | 24 days ago87% |
Declines ODDS (%) | 4 days ago76% | 9 days ago80% |
BollingerBands ODDS (%) | 2 days ago83% | 2 days ago84% |
Aroon ODDS (%) | 2 days ago70% | 2 days ago76% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
ASVIX | 10.10 | 0.06 | +0.60% |
American Century Small Cap Value Inv | |||
VITSX | 152.68 | 0.67 | +0.44% |
Vanguard Total Stock Market Idx I | |||
GCLLX | 17.21 | 0.06 | +0.35% |
Goldman Sachs Enhanced U.S. Equity C | |||
VECRX | 22.33 | 0.07 | +0.31% |
Virtus KAR Equity Income R6 | |||
FBTTX | 25.58 | N/A | N/A |
Fidelity Advisor Biotechnology M |